Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Novartis
Moodys
Accenture
Cantor Fitzgerald
Johnson and Johnson
Medtronic
Colorcon
Citi
Daiichi Sankyo

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,393,208

« Back to Dashboard

Which drugs does patent 9,393,208 protect, and when does it expire?

Patent 9,393,208 protects VIMOVO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.
Summary for Patent: 9,393,208
Title:Method for delivering a pharmaceutical composition to patient in need thereof
Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.
Inventor(s): Ault; Brian (Wilmington, DE), Orlemans; Everardus (Chapel Hill, NC), Plachetka; John R. (Chapel Hill, NC), Sostek; Mark (Wilmington, DE)
Assignee: Pozen Inc. (Chapel Hill, NC) Horizon Pharma USA, Inc. (Deerfield, IL)
Application Number:14/980,639
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Dosage form;

Drugs Protected by US Patent 9,393,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT ➤ Try a Free Trial
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,393,208

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,926,907 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
8,852,636 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
9,220,698 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Try a Free Trial
9,801,824 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Try a Free Trial
8,858,996 Pharmaceutical compositions for the coordinated delivery of NSAIDS ➤ Try a Free Trial
9,161,920 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
9,345,695 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
9,198,888 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
8,865,190 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
8,206,741 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,393,208

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Tunisia 2011000096 ➤ Try a Free Trial
Portugal 1411900 ➤ Try a Free Trial
Norway 2013014 ➤ Try a Free Trial
Norway 333836 ➤ Try a Free Trial
Norway 20035275 ➤ Try a Free Trial
Mexico 2011002515 ➤ Try a Free Trial
Mexico PA03011017 ➤ Try a Free Trial
Morocco 32692 ➤ Try a Free Trial
Luxembourg 91858 ➤ Try a Free Trial
South Korea 20110079641 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Teva
Deloitte
McKesson
Mallinckrodt
US Department of Justice
Daiichi Sankyo
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot